Conover MM, Rothman KJ, Sturmer T, Ellis AR, Poole C, Jonsson Funk M. Propensity score trimming mitigates bias due to covariate measurement error in inverse probability of treatment weighted analyses: a plasmode simulation. Stat Med. 2021 Apr;40(9):2101-12. doi: 10.1002/sim.8887
Webster-Clark M, Sturmer T, Wang T, Man K, Marinac‐Dabic D, Rothman KJ, Ellis AR, Gokhale M, Lunt M, Girman C, Glynn RJ. Using propensity scores to estimate effects of treatment initiation decisions: state of the science. Stat Med. 2021 Mar 30;40(7):1718-35. doi: 10.1002/sim.8866
Talon B, Perez A, Yan C, Alobaidi A, Zhang KH, Schultz BG, Suda KJ, Touchette DR. Economic evaluations of clinical pharmacy services in the United States: 2011-2017. J Am Coll Clin Pharm. 2020 Jun;3(4):793-806. doi: 10.1002/jac5.1199
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 1;12(1):2.
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Stat Med. 2004 Dec 30;23(24):3773-80. doi: 10.1002/sim.2072.